Document is current

Article History

Received: 13 July 2020

Accepted: 26 October 2020

First Online: 7 November 2020

Ethics approval and consent to participate

: The study protocol was approved by: Comitato Etico, Fondazione IRCCS (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; internal reference. no. INT 47/16); Institutional Review Board of University of Tsukuba Hospital (University of Tsukuba, Tsukuba, Japan; internal reference. no. 15-32); National Cancer Center Hospital East Institutional Review Board (National Cancer Center Hospital East, Chiba, Japan; internal reference. no. K0471); Ethics Review Board of Asan Medical Center (Asan Medical Center, Seoul, Republic of Korea; internal reference. no. 2015-0375); Yale University Institutional Review Board #2, 3, 4B, 5—Human Investigation Committee I, II, III, IV (Yale University, New Haven, CT, USA; internal reference. no. 1505015871); METC Brabant gebouw Hasseltveste Tilburg Netherlands (internal reference. no. P1513); OHRPP IRB UCLA Medical Center (University of California Los Angeles, Los Angeles, CA, USA; internal reference. no. 15-000632-AM-0003); NRES Committee South Central – Berkshire, UK (internal reference. no. 15/SC/0306). The study followed the principles outlined in the Declaration of Helsinki. All patients provided written informed consent.

: Not Applicable.

: Andrea Necchi is consultant for: Merck, Roche, BMS, Bayer, GSK, Astellas, Janssen. Nobuaki Matsubara received research funding from Eli Lilly, AstraZeneca, Astellas, Bayer, Janssen, MSD and Sanofi. Daniel Petrylak received consulting fee from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myer Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen. Grant support from Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol Myer Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics. Ronald de Wit received consultancy or speaker fees from Sanofi, Merck, Janssen, Roche, Clovis, and Bayer. Institutional grants from Sanofi, and Bayer. Alexandra Drakaki received grants from Eli Lilly, BMS, AstraZeneca, Seattle Genetics/Astellas. Astra M Liepa, Huzhang Mao and Katherine-Bell McGuinn are employees and Shareholders in Eli Lilly and Company. Tom Powles received consultancy fee from AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics. Received grant/funding from AstraZeneca and Roche. Strategic Advisory for Pfizer, AstraZeneca, Roche, and BMS.